The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set a new standard in another patient group after proving its prowess ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said Tuesday in its quarterly report. Merck, which is facing plummeting sales ...

With high drug prices remaining an ongoing concern for U.S. | A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.

'Now is not the time to retreat': BMS CEO blasts Trump admin tariffs, health reforms amid $40B US investment pledge ...

Summit’s stock price plummeted by nearly 37% following Akeso’s overall survival reveal before a trading halt was initiated.

Novo Nordisk has submitted for FDA approval of an oral version of Wegovy. It would be the world’s first oral GLP-1 obesity treatment.

In short reprieve for pharma, commerce secretary says drug tariffs to come 'in the next month or two' ...

Glenmark Pharma, an India-based drug manufacturer that has been the focal point of a spate of recalls in recent years, issued another. This time it’s for just shy of 1.5 million bottles of the ...

According to Evaluate’s forecasts, all together, the biggest potential drug launches of the coming year stand to generate a whopping $29 billion in annual sales by the end of the decade.

Comparing the FDA new drug approval lists from 2023 and 2024 reveals a significant difference in the size of the companies that achieved the regulatory triumphs. | Each year, many scientists and ...

In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German cancer biotech it acquired earlier this year. | Novartis confirmed ...

Shortly after a similarly sized venture from Pfizer, French pharma juggernaut Sanofi has unveiled a major manufacturing outlay in China, marking its biggest investment in the country to date.